Health
Break-through drug ends HIV 99 percent
A new HIV drug created by Israeli researchers has passed its first human clinical trial.
At end of the trial, it was discovered that the drug, named Gammora, created by Zion Medical, an Israeli biotech company was capable of wiping out 99 per cent of HIV infected cells in the human body.
According to a statement released by the company and available on PR Newswire, Gammora was able to eliminate up to 90 per cent of the virus during the first four weeks of the trial.
Zion Medical developed the drug Gammora in collaboration with the Hebrew University in Jerusalem and the Sirion Biotech in Germany.
The drug is designed to attack and kill the HIV-infected cells in the human body without causing damage to the healthy cells.
In the study, researchers randomly assigned nine participating patients from the Ronald Bata Memorial Hospital in Uganda to receive different doses of Gammora between four to five weeks in July and August of this year.
While the new HIV drug is still in its first stage of exploration, the results have already offered hope that a cure for the dreaded virus is possible.
“Most patients showed a significant reduction of the viral load of up to 90 per cent from the baseline during the first four weeks,” said Dr. Esmira Naftalim, Zion Medical’s head of development.
-
Latest1 week agoLagos NURTW organising secretary Toba Ajiboye dies after gunmen attack
-
Business6 days agoCBN targets $12bn annual Diaspora inflows to boost FX liquidity
-
Business6 days agoSEC launches nationwide campaign to help investors recover unclaimed dividends
-
Business4 days agoNigerian AI researcher champions ethical artificial intelligence at COPA AI 2026 summit in Wales
-
Latest1 week agoOyo APC berates Makinde over call for UN probe into Oriire school rescue
-
Latest7 days agoKwankwaso calls for renewed North–South-East Political alliance ahead of 2027
-
Business6 days agoCBN launches real-time FX tracker for BDCs, tightens oversight of FX market
-
Business5 days agoFood prices now biggest threat to inflation, beyond CBN’s reach – Analysts


